Table 3.

Effect of placebo, USC, and CGM on clinical safety parameters.

Parameters	Time	Groups
		Placebo	USC	CGM
Hb (g/dl)	Baseline	13.63 ± 0.65	13.94 ± 0.48	14.26 ± 0.52
	End of study	14.84 ± 0.47	14.02 ± 0.34	14.35 ± 0.56
RBC count (million/μl)	Baseline	5.78 ± 0.45	4.62 ± 0.23	4.71 ± 0.28
	End of study	5.84 ± 0.71	5.94 ± 0.25	4.44 ± 0.21
PCV (%)	Baseline	43.4 ± 2.43	44.5 ± 3.14	43.9 ± 2.73
	End of study	45.7± 2.15	46.8 ± 2.31	45.6 ± 2.55
MCV (fl/red cell)	Baseline	79.22 ± 6.35	82.59 ± 3.79	80.43 ± 4.58
	End of study	82.78 ± 2.90	84.46 ± 3.81	81.65 ± 3.69
MCH (pg/cell)	Baseline	26.07 ± 1.77	27.82 ± 1.19	25.82 ± 1.65
	End of study	27.15 ± 0.96	25.10 ± 1.23	28.45 ± 1.37
AST (IU/L)	Baseline	26.19 ± 4.61	24.62 ± 4.96	27.55 ± 3.70
	End of study	28.32 ± 4.35	27.27 ± 5.61	24.15 ± 6.75
ALT (IU/L)	Baseline	25.12 ± 5.28	26.11 ± 5.83	25.85 ± 4.33
	End of study	24.56 ± 4.88	23.78 ± 5.91	27.46 ± 3.82
ALP (IU/L)	Baseline	86.34 ± 17.10	82.46 ± 16.81	85.27 ± 10.25
	End of study	81.52 ± 13.75	86.27 ± 15.66	82.78 ± 8.78
S. Creatinine (mg/dl)	Baseline	0.96 ± 0.12	1.05 ± 0.13	0.85 ± 0.25
	End of study	0.98 ± 0.11	1.10 ± 0.14	0.93 ± 0.38

A 2 × 2 repeated measures ANOVA was employed to find out statistical significance and the obtained P-values are provided. A P-value of < 0.05 is considered statistically different.

Hb, hemoglobin; RBC, red blood cells; MCV, mean corpuscular volume; PCV, packed cell volume; MCH, mean corpuscular hemoglobin; AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline phosphatase; S. creatinine, serum creatinine.